LEIOMYOSARCOMA

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This study tests whether Vonescimab can safely shrink or control advanced leiomyosarcoma, a rare soft tissue cancer. About 20 adults who have already tried 1-3 other treatments will receive the drug. The goal is to see if it slows tumor growth with few side effects.

This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or slow advanced leiomyosarcoma, a rare soft-tissue cancer. About 16 adults whose cancer worsened after standard chemotherapy will receive ATRA pills for 3 days before each cemiplimab infusion, then cemip…

This study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…

This study tests whether giving chemotherapy before surgery helps people with high-risk retroperitoneal sarcoma (a rare cancer in the abdomen) live longer without the cancer coming back. About 250 adults with specific sarcoma types will be randomly assigned to receive chemo then …

This study tests a drug called AL3818 (anlotinib) for people with a rare cancer called alveolar soft part sarcoma that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow cancer growth. Participants take AL3818 pills daily, and the…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy can help shrink or control advanced soft tissue sarcomas that cannot be removed by surgery. About 45 adults aged 18-75 with certain sarcoma types will receive the combination as their fir…

This early-phase trial tests a combination of two drugs, gemcitabine and nab-sirolimus, in people with advanced leiomyosarcoma or other soft-tissue sarcomas that have specific genetic changes (TSC1 or TSC2 mutations). The main goal is to find a safe dose and watch for side effect…

This study tests whether a personalized, 3-week course of proton or x-ray radiation before surgery can reduce long-term side effects for adults with soft tissue sarcoma. About 110 participants will have two radiation plans made, and a national team will choose the best one for ea…

This study tests whether adding lurbinectedin to standard chemotherapy (doxorubicin) helps people with metastatic leiomyosarcoma live longer without their cancer growing. About 450 adults who have not had prior treatment for advanced disease will receive either the combination or…

This study tests whether taking regorafenib for up to 12 months after initial treatment can delay or prevent bone sarcoma from coming back. About 168 patients with various bone sarcomas will be randomly assigned to receive the drug or just be monitored. The goal is to see if the …

This study looks at 200 people with metastatic leiomyosarcoma who are starting chemotherapy. Researchers collect blood samples before and during treatment to measure circulating tumor DNA (ctDNA) and see if changes in ctDNA can predict tumor shrinkage or longer survival. The goal…

This study looks at whether a blood test (ctDNA) and special scans can help predict how well chemotherapy works in people with a rare cancer called leiomyosarcoma. About 40 participants will give blood samples and have scans before, during, and after treatment. The goal is to fin…